Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treating Atopic Dermatitis With Abrocitinib and Its Impact in Real Life: An Observational Cohort Study To Describe the Effectiveness of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis.

NCT05689151 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05689151
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05689151 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treating Atopic Dermatitis With Abrocitinib and Its Impact in Real Life: An Observational Cohort Study To Describe the Effectiveness of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis.
Lead sponsor
Pfizer
Phase
Observational
Overall status
Recruiting
Start date
March 9, 2023
Completion date
December 31, 2027
Enrollment
183 (estimated)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis, eczema